Sarepta gene therapy study missed key target in Duchennes, page-332

Sammy,

Merck paid $1.9B for a Phase 1 asset...

ANP's DMD Phase 2 IP with ODD and PRV...can be argued has more potential.

Diamond announced a year ago that Big Pharma had made unwanted approaches.

The at AGM, Moses included more commentary in the AGM preso.

It's clear the data room has been open for a year...

FDA meeting in 6 weeks and final trial design for EMA may bring out potential suitors.

If not - then the Board need to bring in $35m to go alone in EMA.

Sarepta has the most to lose at this point in time...everything points to them being involved going forward, somehow.

.